Want to see IN:WOCKPHARMA full AI Analyst Report?
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,086.80 - ₹2,420.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)66.93K
Market Cap
₹304.59B
Enterprise Value₹210.41B
Total Cash (Recent Filing)₹6.80B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)74.6
Beta1.26
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.27%
Share Statistics
EPS (TTM)25.16
Shares Outstanding162,485,570
10 Day Avg. Volume54,415
30 Day Avg. Volume66,933
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.86
Price to Sales (P/S)5.66
P/FCF Ratio298.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And GrowthRecent revenue growth indicates improving commercial traction across the company’s pharmaceutical portfolio. If sustained, the stronger top line can support operating leverage, provide resources for product development, and reinforce Wockhardt’s presence in domestic and international markets over coming quarters.
Return To ProfitabilityThe return to positive net income is a meaningful improvement after several loss-making years. It provides evidence that the recovery is reaching the bottom line, potentially strengthening internal funding capacity and supporting more stable execution if profitability persists.
Improved Balance-sheet CushioningStable debt alongside a larger equity base improves the company’s financial cushion relative to prior years. This supports greater resilience through operating volatility and leaves more flexibility to fund pharmaceutical development, manufacturing capabilities, and market expansion.
Bears Say
Multi-year Earnings And Margin VolatilityThe extended history of losses and uneven operating profitability raises questions about the durability of the latest recovery. Persistent earnings volatility can weaken planning visibility, limit reinvestment capacity, and make future results more sensitive to execution and product-mix changes.
Uneven Cash ConversionPositive operating cash flow is encouraging, but modest free cash flow and its sharp year-over-year decline indicate that profits are not converting consistently into deployable cash. Continued volatility could constrain self-funded investment and reduce flexibility during weaker periods.
Regulatory And Generic-market PressureThe business relies on maintaining regulatory approvals and compliant manufacturing access, while generic medicines remain exposed to pricing competition. These structural factors can pressure margins or restrict market access, making durable growth dependent on successful compliance and product differentiation.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1086.80 and its highest was ₹2420.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹304.59B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Nov 09, 2026 which is in 17 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on Aug 10, 2026. The company reported ₹6.523 earnings per share for the quarter.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of 1.27%. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹6.523 in its last earnings report. Following the earnings report the stock price went down -4.36%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Technical Analysis
Ajanta Pharma Limited
―
Alkem Laboratories Ltd.
―
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―